Infectious Disease Testing Market to Grow with a CAGR of 7.71% through 2030F
Increasing prevalence of emerging diseases and
technological advancement in advanced diagnostic technologies is expected to
drive the Global Infectious Disease Testing Market growth in the forecast
period, 2026-2030.
According to TechSci
Research report, “Infectious Disease Testing Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2030”, the
Global Infectious Disease Testing Market stood at USD 34.09 billion in 2024 and
is anticipated to grow with a CAGR of 7.71% in the forecast period, 2026-2030.
The growth of the global infectious disease testing market is primarily driven
by the increasing prevalence of infectious diseases such as hepatitis,
influenza, and HIV. There is a rising demand for point-of-care diagnostic tests
and increased funding from both private and government organizations for
diagnostic service centers. Advancements in technologies in the field of
infectious disease diagnostics contribute to this growth.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Infectious Disease Testing
Market”
The global geriatric
population is on the rise, with over 727.0 million individuals worldwide
falling into the 65 and above age group. Due to factors such as multimorbidity,
reduced immune function, and physiological changes associated with aging, the
elderly are more vulnerable to COVID-19. In 2021, the CDC reported that 80% of
COVID-19-related deaths occurred in individuals over 65 years old.
Consequently, continuous testing of this demographic is crucial to prevent
severe infections, presenting growth opportunities for molecular diagnostic
tests in countries like Russia, Japan, and the U.S., which have the highest
elderly populations globally. Given the diverse nature of infectious diseases
and the increasing resistance of causative agents, it is imperative that the
infectious disease molecular diagnostics test menus remain dynamic and
comprehensive. For example, when the coronavirus outbreak in China was declared
a global health emergency by the WHO in January 2020, RT-PCRs and sequencing
tools were employed to identify and characterize the virus.
An anticipated increase
in external funding for conducting clinical studies in infectious disease
molecular diagnostics is expected to drive market growth. Funding plays a
significant role in the product development process.
Other key drivers of
market expansion include the rising prevalence of infectious diseases, the
shift towards point-of-care testing from centralized laboratories, and
increased R&D activity in infectious disease diagnostics. Scientific
research and development efforts in developing novel technologies and
techniques, such as mass spectrometry and next-generation sequencing (NGS),
have led to the evolution of rapid diagnostics for disease detection, further
fueling market growth. For instance, according to an article by Frontiers in
February 2022, non-typhoidal Salmonella causes nearly 93.8 million cases of
gastroenteritis globally each year, highlighting the need for effective
diagnostics. The increasing preference for point-of-care testing by end users
is also expected to drive market expansion.
Point-of-care
diagnostics provide quick and valuable information for patient care,
particularly where the disease is being experienced. Consequently, several
companies are focusing on research and development initiatives to create
point-of-care diagnostic solutions for developing nations. Major market players
are constantly updating their product lines through the introduction of new
products, joint ventures, mergers, and acquisitions, all of which contribute to
the expansion of the global study market.
The increase in the
number of medical laboratories for infectious disease diagnostic testing is
anticipated to contribute to market growth. In 2020, the Government of India
announced the launch of three state-of-the-art high-throughput Indian Council
of Medical Research labs in Kolkata, Mumbai, and Noida, aimed at increasing
COVID-19 testing capacity. These labs are not only used for COVID-19 tests but
also for the diagnosis of other infectious diseases such as HIV, hepatitis,
tuberculosis, and dengue. The rise in awareness among individuals for early
diagnosis and management of infectious diseases, along with the increase in
information technology systems to develop advanced diagnostic devices, is
expected to provide lucrative opportunities for the expansion of the global
infectious disease testing market during the forecast period.
Therefore, technological
advancements in diagnostic instruments and increased awareness regarding early
diagnosis are driving market growth. However, the high cost associated with
diagnostic instruments and the lack of skilled technicians are expected to
restrict market growth during the forecast period.
The Global Infectious
Disease Testing Market is segmented into product & service, technology,
disease, end user, regional distribution, and company.
Based on disease, the
segment of the Human Immunodeficiency Virus (HIV) is projected to hold a
significant market share during the forecast period. The study anticipates
substantial growth in this segment. According to the updated data from the
Minority of HIV/AIDS Fund (MHAF), United States Department of Health and Human
Services Statistics in June 2021, there were approximately 37.6 million people
living with HIV worldwide in 2020, including 35.9 million adults and 1.7
million children under the age of 15. The same source also estimates that
around 1.5 million people globally contracted HIV in 2020. The increasing
prevalence of HIV and the demand for diagnostic tests and detection are driving
the market expansion.
The Human Rights
Campaign (HRC) Foundation and "Us Helping Us" launched the first
in-home HIV testing program for residents in the United States in August 2021.
This initiative, along with other global efforts, is expected to contribute to
market growth during the forecast period, as it raises awareness about HIV. The
market's expansion will be accelerated by new research and developments,
technological advancements, and the introduction of technologically enhanced
products by key competitors. For instance, Altona Diagnostics One introduced
the 1.5 AltoStar HIV RT-PCR Kit in April 2021, an in-vitro diagnostic test that
uses real-time RT-PCR technology to identify and quantify HIV-specific RNA in
human plasma. Therefore, considering the increasing HIV infections, ongoing
research and developments, and technological advancements, the Human
Immunodeficiency Virus (HIV) segment is expected to experience significant
growth over the forecast period.
Based on technology, Molecular
diagnostics is the dominant segment in the global infectious disease testing
market, primarily due to its high accuracy, sensitivity, and ability to detect
pathogens at the genetic level. This method enables early and precise
identification of a wide range of infectious agents, including viruses,
bacteria, and fungi, making it invaluable in clinical decision-making and
outbreak management. The demand for molecular diagnostics surged during the
COVID-19 pandemic, as RT-PCR became the gold standard for virus detection.
Beyond COVID-19, molecular techniques are widely used for diagnosing infections
such as HIV, hepatitis, tuberculosis, and HPV. The adoption of multiplex PCR
and real-time PCR technologies has further strengthened the segment, allowing
simultaneous detection of multiple pathogens from a single sample. Advancements
in automation, portability, and the development of rapid molecular
point-of-care tests have expanded their use beyond centralized laboratories to
clinics and remote settings. These advantages, combined with ongoing
innovations in genomics and precision medicine, ensure molecular diagnostics
maintains its leadership in infectious disease testing.
Based on region, Asia-Pacific
is the fastest-growing region in the global infectious disease testing market
due to several key factors. The region faces a high burden of infectious
diseases such as tuberculosis, hepatitis, dengue, and emerging zoonotic
infections, driving demand for early and accurate diagnostics. Rapid
urbanization, dense populations, and variable hygiene conditions contribute to
frequent outbreaks, making effective testing essential. Governments across
Asia-Pacific are increasing healthcare investments, strengthening disease
surveillance programs, and promoting early diagnosis to combat public health
threats. In parallel, rising healthcare awareness and improving access to
medical services, especially in countries like India, China, and Southeast
Asian nations, are expanding the reach of diagnostic testing.
The growing presence of
local diagnostic manufacturers, advancements in molecular and point-of-care
technologies, and strategic partnerships with global healthcare players are
accelerating innovation and affordability. These combined factors position Asia-Pacific
as a dynamic and rapidly expanding market within the global infectious disease
diagnostics landscape.
Major companies
operating in Global Infectious Disease Testing Market are:
·
Biomérieux
SA
·
Abbott
Laboratories Inc.
·
Becton,
Dickinson and Company
·
Bio-Rad
Laboratories Inc.
·
Danaher
Corporation
·
F.
Hoffmann-La Roche AG
·
Siemens
Healthineers AG
·
Thermo
Fisher Scientific Inc.
·
Quidel
Corporation
·
Trinity
Biotech PLC
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“The global infectious
disease testing market is experiencing robust growth, driven by factors like
the rising prevalence of infectious pathogens, heightened public health
awareness, and the increasing emphasis on early diagnosis and prevention.
Technological innovations such as molecular diagnostics, rapid point-of-care
assays, and multiplex testing are expanding access to faster, more accurate
results. The growth in decentralized healthcare settings, including remote
clinics and home testing, is fueling demand. Frequent outbreaks ranging from
seasonal influenza to emerging diseases like mpox, have prompted governments
and private players to bolster screening programs and invest in diagnostic
infrastructure. However, the innovations, expanded testing coverage, and
proactive health initiatives are propelling sustained market expansion” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Infectious Disease
Testing Market Segmented By Product & Service (Assays, Kits, &
Reagents, Instruments, Services & Software), By Technology (Molecular
Diagnostics, Immunoassay, Microbiology, Others), By Disease (Hepatitis, Human
Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB),
Hospital-Acquired Infections (HAIs), Others), By End User (Hospital and
Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research
Institutes, Others), By Region
and Competition, Forecast &
Opportunities, 2020-2030F”, has evaluated the
future growth potential of Global Infectious Disease Testing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Infectious Disease Testing Market.
Contact
TechSci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: sales@techsciresearch.com
Web: https://www.techsciresearch.com